menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
ReachMD Faculty

Public Profile

Daniel P. Petrylak, MD
Daniel P. Petrylak, MD
  • Professor of Medicine (Medical Oncology)
  • Columbia University Medical Center
  • Co-Director
  • Signal Transduction Research Program
Daniel P. Petrylak, MD was appointed to lead the genitourinary cancers medical oncology team at Smilow Cancer Hospital as director of the prostate cancer research group, Professor, and co-director of the Signal Transduction Research Program. Dr. Petrylak joined Yale from New York-Presbyterian Hospital/Columbia University Medical Center, where he served as a Professor of Medicine and began his appointment in September of 2012. Dr. Petrylak is a member of the American Association for Cancer Research, American Society for Clinical Oncology, American College of Physicians, American Association for the Advancement of Science, American Urological Association, and the Southwest Oncology Group. Dr. Petrylak currently serves as the Principal Investigator or co-Principal Investigator on 9 Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. He has led the advanced bladder cancer subcommittee for SWOG since 1995. He additionally has led multiple national and international studies in prostate and bladder cancer. Dr. Petrylak’s research interests span both prostate and bladder cancer. He led an investigator initiated trial of docetaxel and estramustine in castration resistant prostate cancer. The results of this study, supported a phase 3 trial of this combination in SWOG led by Dr.Petrylak. The results of this study supported the FDA approval of docetaxel for castration resistant prostate cancer. This was one of the first two trial to demonstrate a survival benefit in this state of disease. Dr. Petrylak has also been instrumental in the development of immunotherapy and targeted therapies for refractory bladder cancer. His work with Enfortumab Vedotin is currently being submitted to the FDA for accelerated approval. Dr. Petrylak received his undergraduate degree from Columbia College and his medical degree from Case Western University School of Medicine. He completed his internship and residency at Albert Einstein College of Medicine and his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center. He has authored more than 140 peer-reviewed articles and book chapters on prostate and bladder cancer research outcomes.
LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/2/20